Mammoth Biosciences

Mammoth Biosciences

CRISPR-based diagnostic platform developer

Overview

Mammoth Biosciences uses CRISPR technology to create rapid molecular diagnostic tests that can identify diseases, including COVID-19, at or near the point of care. Its CRISPR-based platform detects genetic material from pathogens, enabling quick, on-site results that patients can discuss with healthcare providers without sending samples to distant labs. The company earns revenue through partnerships (such as with GSK Consumer Healthcare) and the sale of its diagnostic products and services to healthcare providers and research institutions. By collaborating with scientists and institutions, Mammoth aims to expand the range of conditions its platform can detect and to improve the speed and accessibility of diagnostic testing. In short, Mammoth Biosciences focuses on practical, fast, and accessible molecular diagnostics built on CRISPR technology, targeting healthcare and research markets with a goal of broadening rapid testing options globally.

About Mammoth Biosciences

Simplify's Rating
Why Mammoth Biosciences is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$363.2M

Headquarters

Brisbane, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Regeneron invests $95M upfront, up to $370M per target plus royalties in April 2024 deal.
  • VedaBio licenses diagnostic CRISPR tech on September 9, 2025, expanding revenue streams.
  • Preclinical APOC3 data presented at ASGCT May 2024 shows triglyceride reduction in NHPs.

What critics are saying

  • Intellia Therapeutics' clinical NTLA-2001 captures Regeneron priority over Mammoth's preclinical programs.
  • Beam Therapeutics' 90% base editing efficiency in non-liver tissues surpasses Cas14 systems.
  • FDA scrutiny halts Casφ programs after CTX112 holds, delaying pipeline 18 months.

What makes Mammoth Biosciences unique

  • Ultracompact CRISPR systems like CasΦ enable in vivo editing in hard-to-reach tissues.
  • DETECTR platform delivers first CRISPR-based EUA for high-throughput COVID-19 testing.
  • Co-founded by Nobel laureate Jennifer Doudna with exclusive Cas12, Cas13, Cas14 licenses.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$363.2M

Above

Industry Average

Funded Over

7 Rounds

Notable Investors:
Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison
Coming Soon

Benefits

Medical, dental, & vision

401(k)

Unlimited vacation

Transportation subsidy

Onsite amenities

Happy hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

1%
HealthTech HotSpot
Jan 9th, 2026
Mammoth Biosciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Mammoth Biosciences to present at 44th Annual J.P. Morgan Healthcare Conference. BRISBANE, Calif. - (BUSINESS WIRE) - #CRISPR - Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation in vivo CRISPR gene editing platform to create potential one-time curative therapies, today announced its participation in the upcoming 44th Annual J.P. Morgan Healthcare Conference. Trevor Martin, Ph.D., co-founder and CEO, will provide a corporate overview with key business updates related to Mammoth Biosciences' pipeline and platform on Thursday, January 15 at 7.30 am PT in San Francisco. About Mammoth Biosciences Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company's ultracompact systems are designed to be more specific and packageable to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, reverse transcriptase editing, and epigenetic editing. The company is building out its wholly owned pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology platform. Mammoth Biosciences' deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the promise of CRISPR technologies. For more information, please visit www.mammoth.bio or follow Mammoth on LinkedIn or X. Media Contact: Mohana Ray Email: [email protected] Phone: 312-506-5210

CRISPR Medicine News
Oct 1st, 2025
Mammoth Biosciences to Present Preclinical Data on MB-111 at the European Society of Gene & Cell Therapy 32nd Annual Congress

Mammoth Biosciences to present preclinical data on MB-111 at the European Society of Gene & Cell Therapy 32nd Annual Congress.

360Dx
Sep 9th, 2025
VedaBio Licenses Mammoth Biosciences Diagnostic CRISPR Technology

NEW YORK - VedaBio has entered into a nonexclusive licensing agreement with Mammoth Biosciences for the use of certain Mammoth CRISPR-based technologies for diagnostic applications, the firms announced on Tuesday.

Labiotech.eu
Oct 10th, 2024
12 Biotech Unicorns Revolutionizing The Future Of Healthcare

Have you ever heard of a biotech unicorn? Although a mythological creature might be what first springs to mind, a unicorn in the business world actually refers to a privately owned company valued at more than $1 billion. Some world-renowned former unicorns include Airbnb, Facebook, and Google. The reason they are called “unicorns” is because it is traditionally very rare for a company to achieve this valuation.In the biotech world, there are only a select few companies with unicorn status that are working on therapeutics. In this article, we take a closer look at 12 biotech unicorns rated in order of their valuations according to CB Insights.Table of contentsAbogen BiosciencesAbogen Biosciences is a Chinese biotech company and is valued at $3.7 billion. This comes as no surprise after it raised $700 million in series C funding back in August 2021, marking one of the largest private biotech funding rounds ever and obliterating the fundraising record for a Chinese mRNA vaccine developer. It then followed this round with another impressive series C+ round in November of the same year, in which it raised $300 million.Abogen is part of a rare breed of Chinese biotechs, having actually developed all of its key messenger RNA (mRNA) platform technologies itself, across mRNA synthesis, delivery, and manufacturing

Securities.io
Jul 16th, 2024
Investing In Noble Prize Achievements – Crispr For Precise Genetic Engineering

The Nobel Prize is the most prestigious award in the scientific world. It was created according to Mr. Alfred Nobel's will to give a prize “to those who, during the preceding year, have conferred the greatest benefit to humankind” in physics, chemistry, physiology or medicine, literature, and peace. A sixth prize would be later on created for economic sciences by the Swedish central bank.Who to attribute the prize to belongs to multiple Swedish academic institutions.Legacy ConcernsThe decision to create the Nobel Prize came to Alfred Nobel after he read his own obituary, following a mistake by a French newspaper that misunderstood the news of his brother's death. Titled “The Merchant of Death Is Dead”, the French article hammered Nobel for his invention of smokeless explosives, of which dynamite was the most famous one.His inventions were very influential in shaping modern warfare, and Nobel purchased a massive iron and steel mill to turn it into a major armaments manufacturer. As he was first a chemist, engineer, and inventor, Nobel realized that he did not want his legacy to be one of a man remembered to have made a fortune over war and the death of others.Nobel PrizeThese days, Nobel's Fortune is stored in a fund invested to generate income to finance the Nobel Foundation and the gold-plated green gold medal, diploma, and monetary award of 11 million SEK (around $1M) attributed to the winners.Often, the Nobel Prize money is divided between several winners, especially in scientific fields where it is common for 2 or 3 leading figures to contribute together or in parallel to a groundbreaking discovery.Over the years, the Nobel Prize became THE scientific prize, trying to strike a balance between theoretical and very practical discoveries

Recently Posted Jobs

Sign up to get curated job recommendations

Mammoth Biosciences is Hiring for 2 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →